Chris Rhodes

Chris Rhodes Email and Phone Number

Founder and CEO @ Propel Biologics, Inc
San Diego, CA, US
Chris Rhodes's Location
San Diego, California, United States, United States
About Chris Rhodes

Biopharmaceutical executive with over 25 years R&D leadership experience in pharmaceutical, biotechnology, delivery, and device companies. Start-up specialist adept at growing new technologies and translating research concepts to product development and commercialization. Experienced drug development business leader for complex combination products integrating discovery, development, manufacturing, and marketing teams. Board level review and communication of project strategy, operational plans and budget.Played a key role in the development of commercial products Byetta (exenatide injection for Type 2 diabetes, FDA 2005), Lusedra (propofol prodrug, FDA 2008), Bydureon (exenatide extended-release injectable suspension, FDA 2012), Myalept (metreleptin for severe lipodystrophy, FDA 2014), Afrezza (insulin inhalation powder for diabetes, FDA 2014)Expertise in biologics research, delivery system research and development, and translation to product development, clinical development, and commercialization, with special emphasis in diabetes and metabolic diseases, long-acting injectables, and oral delivery technologies.Specialties: Long-Acting Injectables • Oral Delivery Device and Formulation Technology • Advanced Delivery and Device Technology • Polymers • Conjugates • Lipids • Nanotechnology • Microfabrication • Inhalation • Transdermal • Ocular • Oral • Pumps • Injection Systems • Peptide • Protein • Antibody • Insulin • GLP-1 • Leptin • Avastin • Small Molecule • Drug Development • Diabetes • Neuropathic Pain • Obesity • Metabolic Disease • Anesthesiology • Ophthalmology • Retina • Glaucoma • Technology Assessment • Business Development • Due Diligence • Competitive Intelligence • Life Cycle Strategy

Chris Rhodes's Current Company Details
Propel Biologics, Inc

Propel Biologics, Inc

View
Founder and CEO
San Diego, CA, US
Chris Rhodes Work Experience Details
  • Propel Biologics, Inc
    Founder And Ceo
    Propel Biologics, Inc
    San Diego, Ca, Us
  • Baywind Bioventures, Llc
    President And Founder
    Baywind Bioventures, Llc 2014 - Present
    Baywind Bioventures is a business investment and advisory firm with emphasis in biopharmaceuticals, the food and beverage industry, and higher education. Leadership has 50 years of experience in corporate product development in Fortune 100 consumer products and biotechnology companies, substantial startup experience, and academic administration.
  • Cass Pharmaceuticals
    Chief Scientific Officer And Co-Founder
    Cass Pharmaceuticals Feb 2020 - Present
    CASS is developing delivery enabled pharmaceutical products. Founded by a team of experienced executives in the biopharmaceutical and drug delivery technology space.
  • Sensulin, Llc
    Chief Technology Officer And Co-Founder
    Sensulin, Llc Feb 2014 - Present
    Head of product development, responsible for translating delivery technology from late stage research through clinical proof of concept.First product is glucose-responsive insulin designed to improve glycemic control in patients using insulin. Responsible for technology R&D, intellectual property, scale-up, manufacturing, product development and business development. - Key technical lead for company supporting business development and financing discussions- Set up and run R&D laboratory developing proprietary technology for triggered release- Submitted SBIR, NIH, and JDRF grants
    View
  • Biopharmaceutical Industry
    Board And Advisory Positions
    Biopharmaceutical Industry 2005 - Present
    Advisory Council, Keck Graduate Institute (2016-present)President, Boulder Peptide Symposium (2016-present)Chair of Scientific Advisory Board and Board of Trustees, Boulder Peptide Symposium (2011-2016)Domain Expert, CONNECT Springboard Program for entrepreneurs (2011-present)Advisory Board, UCSD Biomedical Engineering (2009-present)Industrial Advisory Board, UCSD Institute for Engineering and Medicine (2008-present)Organizing Committee and Symposium Chair, TIDES Annual meeting (2005-present)Editorial Board, Expert Opinion in Drug Delivery (2008-present)Pharmaceutics instructor, UCSD Skaggs School of Pharmacy (2005-present)
  • Drug Delivery Experts, Llc
    President, Ceo, And Founder
    Drug Delivery Experts, Llc May 2014 - Jul 2021
    Drug Delivery Experts, a specialty CDMO with small scale parenteral fill finish capabilities was sold to Pace Life Sciences in July 2021. Built the company from the ground up and sold as a profitable business.
  • Christopher A Rhodes & Associates, Llc
    President
    Christopher A Rhodes & Associates, Llc Jan 2011 - May 2014
    Pharmaceutical product development consulting• Interim leadership and management
• Direct technical R&D support
 • Portfolio strategy and life cycle plans
• Technology evaluation and due diligence

Clients include start-up to fully integrated pharma to venture firms with interest in biopharmaceutical, drug delivery, device, specialty pharmaceutical products and technologies.- Developed injectable formulation and device delivery systems for several biopharmaceuticals- Developed non-invasive delivery systems for several biotech firms (nasal, pulmonary, oral)- Completed due diligence for delivery technology license / acquisition for major firms in ophthalmology, generic, pharmaceutical, and venture- Defined delivery and product development strategy and life cycle plans for peptide programs at several biotechnology companies (diabetes, obesity, sexual dysfunction, neurology)- Submitted two SBIR grants for novel technologies and therapeutics, one funded in 2012
  • Sks Ocular, Llc
    Chief Technology Officer
    Sks Ocular, Llc Jul 2011 - Nov 2012
    Head of product development for ocular company advancing novel technologies from research to clinical concept for small molecules and biologics, responsible for technology R&D, intellectual property, scale-up, manufacturing, project and business development.- Key technical lead for company supporting business development and financing discussions- Set up and ran R&D laboratory developing proprietary microfabrication technology for sustained release protein delivery in biodegradable polymers- Completed feasibility for sustained release injection platform (five organics, three proteins)- Developed nanoparticle formulations for protein stabilization and sustained delivery- Developed process and scale-up technologies for platform product supply- Work resulted in numerous intellectual property disclosures and provisional applications- Submitted SBIR grant for dry AMD research models and diagnostics
  • Amylin Pharmaceuticals
    Executive Director, Pharmaceutical R&D
    Amylin Pharmaceuticals 2004 - 2011
    San Diego, Ca, Us
    Amylin Pharmaceuticals is a mid-sized biotechnology company engaged in the discovery, development, and commercialization of peptides and proteins for diabetes and obesity, has two commercial products (Symlin and Byetta) and a polymer microsphere delivery system in development which is the basis for Bydureon (currently under FDA and EMA review).• Head of pre-formulation, drug delivery, bio-analytical chemistry responsible for peptide and protein development from discovery through commercial (35 staff, $10-15M annual budget)• Head of the drug delivery program responsible for strategy, technology identification, feasibility studies, development candidate selection, clinical testing ($20M annual budget)• Delivery strategy leader for corporate partnership (Eli Lilly, Takeda, Biocon, Psylin) portfolios in diabetes, obesity, depression consistent with platform technology vision• Led the Amylin-Lilly Alliance drug delivery program through preclinical and clinical testing of nasal, pulmonary, transdermal, and oral technologies for exenatide ($20M annual budget)• Negotiated licenses for technologies including upfront fees up to $8M, clinical milestone fees totaling up to $29M, escalating royalties for single and multiple products in a platform• Served as operating committee leader from due diligence through license termination• Completed regulatory submissions and clinical studies in diabetes and obesity for nasal, transdermal, and sustained release injectable formulations (IND, NDA, BLA filings)
    View
  • Guilford Pharmaceuticals
    Senior Director, Pharmaceutical Development
    Guilford Pharmaceuticals 1998 - 2004
    Us
    Guilford Pharmaceuticals (later MGI and then Eisai) was a small pharmaceutical company engaged in CNS drug discovery and development with a commercial product (Gliadel wafer) for brain cancer, and a polymer microsphere delivery system in development.• Head of pre-formulation, formulation development, analytical chemistry responsible for small molecule and polymer delivery system development (45 staff, $10M annual budget)• Responsible for lead molecule selection, transition to clinical development, and development of formulations and clinical supply for development• Led cross-functional clinical development teams for new therapeutics in peripheral diabetic neuropathy and procedural sedation (30 staff, $5-10M annual budget)• Developed commercial launch configuration for intravenous injection (propofol pro-drug)• Developed immediate, controlled release, and chewable tablet prototypes for commercial formulation for a high dose drug for Parkinson’s disease• Completed regulatory submissions for phase 1 and 2 studies in procedural sedation and diabetic neuropathy programs (INDs)
    View
  • Mannkind Corporation
    Vice President, R&D
    Mannkind Corporation 1992 - 1998
    Danbury, Ct, Us
    Pharmaceutical Discovery Corporation (later Mannkind) was a start-up engaged in discovery and development of fluorescent diagnostic systems, an Alzheimer's drug, and the Technosphere inhalation delivery system which is the basis for the product Afrezza (currently under FDA review).• Head of formulation, chemistry, biology, pharmacokinetics (20 staff, $5M annual budget)• Responsible for design, synthesis, and development of a propriety drug delivery technology• Team leader for partnership and collaborative drug delivery contract work, the primary revenue generator for the company (contracts up to $1M)• Developed inhalation dry powder formulations of insulin, calcitonin, parathyroid hormone• Developed protein formulation for subcutaneous infusion and small molecule suspension formulation for intravenous injection• Designed and synthesized muscarinic receptor antagonists for cognitive disorders • Developed fluorescent receptor ligands for high-throughput screening and antibody-based diagnostic kit for hypertension (510k)
    View

Chris Rhodes Education Details

  • Yale University
    Yale University
    Chemistry
  • Ucla
    Ucla
    Chemistry
  • New York University
    New York University
    Chemistry

Frequently Asked Questions about Chris Rhodes

What company does Chris Rhodes work for?

Chris Rhodes works for Propel Biologics, Inc

What is Chris Rhodes's role at the current company?

Chris Rhodes's current role is Founder and CEO.

What schools did Chris Rhodes attend?

Chris Rhodes attended Yale University, Ucla, New York University.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.